Physician profile
Joe Mobley
NPI 1356597983
$18,239.74
in general payments reported to CMS, 2019-2025
28 companies · $4,115 in 2025
The $4,115 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $3,779 · 2021: $1,786 · 2022: $1,447 · 2023: $4,365 · 2024: $1,633 · 2025: $4,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,064 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Travel and Lodging: $1,099 · Honoraria: $350 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,064.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Travel and Lodging | $1,099.36 |
| Honoraria | $350.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,233.20 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $4,017.85 | 2019-2020 | |
| Axonics, INC. | $2,715.92 | 2020-2024 | Axonics, Bulkamid |
| Angiodynamics, INC. | $1,970.32 | 2025 | Nanoknife |
| Olympus America INC. | $1,077.80 | 2019-2025 | Itind System |
| Boston Scientific Corporation | $872.72 | 2022-2025 | Axonics, Upsylon, Solyx Sis System |
| Astellas Pharma US INC | $603.98 | 2019-2023 | Veozah |
| Teleflex LLC | $497.08 | 2022-2025 | Barrigel, Urolift |
| Pfizer INC. | $349.22 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $305.30 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $242.86 | 2019-2025 | Erleada, Akeega, Balversa |
| Urogen Pharma, INC. | $196.55 | 2021-2024 | |
| Endo Pharmaceuticals INC. | $190.54 | 2019-2022 | |
| Abbvie INC. | $170.26 | 2019-2025 | |
| Procept Biorobotics Corporation | $135.43 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $106.69 | 2020-2022 | |
| Coloplast Corp | $77.41 | 2021-2025 | |
| Tolmar, INC. | $75.86 | 2024-2025 | Eligard, Jatenzo |
| Bioprotect Medical, INC. | $63.89 | 2025 | Bioprotect Balloon Implant System |
| Myriad Genetic Laboratories, INC. | $57.83 | 2022 | |
| Sun Pharmaceutical Industries INC. | $46.45 | 2024 | |
| Photocure INC | $45.68 | 2022-2023 | Cysview |
| Myovant Sciences INC. | $43.86 | 2021-2022 | |
| Caldera Medical, INC | $41.48 | 2020-2021 | |
| Valencia Technologies Corporation | $34.66 | 2025 | Ecoin Device Kit |
| Merck Sharp & Dohme LLC | $25.08 | 2024 | Keytruda |
| Ferring Pharmaceuticals INC. | $23.05 | 2025 | Adstiladrin |
| Endo USA, INC. | $18.77 | 2025 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.